ID   HepG2-GS
AC   CVCL_H214
SY   GS-HepG2
DR   CLO; CLO_0050857
DR   BioSample; SAMN03472118
DR   RCB; RCB1681
DR   Wikidata; Q54882850
RX   DOI=10.1016/j.enzmictec.2004.08.027;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: HGNC; 4341; GLUL.
CC   Derived from sampling site: Liver.
ST   Source(s): RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9,13
ST   D16S539: 12
ST   D5S818: 11,12
ST   D7S820: 10
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 20-05-21; Version: 17
//
RX   DOI=10.1016/j.enzmictec.2004.08.027;
RA   Omasa T., Yamanaka M., Tanimura N., Katakura Y., Kishimoto M.,
RA   Suga K.-I., Enosawa S.;
RT   "Expression and amplification of glutamine synthetase gene endows
RT   HepG2 cells with ammonia-metabolizing activity for bioartificial liver
RT   support system.";
RL   Enzyme Microb. Technol. 35:519-524(2004).
//